Trial
NCT05744401
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Alector Inc.
Collaborators
AbbVie
Condition
Alzheimer's Disease
Intervention
AL002
Why stopped
Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-25